EUVIMEDObjevte EUVIMED
Übersichtsarbeit

NSD3: A Promising Target for Cancer Therapy

Ting Huang, Bowen Zhang, Yifan Yang, Qiong Lin, Genbao Shao

Cell Biochemistry and Function · 2025

DOI: 10.1002/cbf.70071 ↗

At a glance

Übersichtsarbeit in Cell Biochemistry and Function, 2025. Written by Ting Huang and 4 co-authors. Institution: Department of Basic Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China. Major MEDLINE topics: Neoplasms, Histone-Lysine N-Methyltransferase, Antineoplastic Agents, Enzyme Inhibitors. Cited 3 times so far (Crossref); 89 references. Funded by: This study was supported by the Key Research and Development Program of Jiangsu Province (grant no. BE2020678)..

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Over the past 24 years, nuclear receptor‐binding SET domain protein 3 (NSD3) has emerged as a critical regulator of cellular physiological processes. As a histone methyltransferase targeting H3K36, NSD3 catalyzes the addition of methyl groups to histone residues, a process that profoundly influences genome imprinting, gene transcription, and genome stability, thereby modulating gene expression. Amplification, mutations, and fusion events involving the NSD3 gene have been strongly linked to the pathogenesis of various cancers, highlighting its role as a key regulator of tumorigenesis. This review provides an overview of the general structure and biological functions of NSD3, followed by an analysis of NSD3's role in relation to the hallmarks of cancer as described by Hanahan and Weinberg. Targeting NSD3 has become a major focus of research, with significant efforts directed toward the development and clinical application of NSD3 inhibitors. However, challenges related to specificity and selectivity have hindered progress in this area. Despite these obstacles, the successful development and clinical advancement of other histone methyltransferase inhibitors have provided encouragement to researchers, driving the active pursuit of NSD3‐targeted therapies for cancer treatment.

Subjects

MeSH terms (MEDLINE)

NeoplasmsHistone-Lysine N-MethyltransferaseAntineoplastic AgentsEnzyme InhibitorsNuclear ProteinsHumansMolecular Targeted TherapyAnimals

Author keywords

NSD3cancermethylationmethyltransferasesignaling pathwaytherapeutic target

Substances

Histone-Lysine N-MethyltransferaseNSD3 protein, humanAntineoplastic AgentsEnzyme InhibitorsNuclear Proteins

Authors and institutions

  • Department of Basic Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.
  • Institute of Urinary System Diseases, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, China.

Funding

  • This study was supported by the Key Research and Development Program of Jiangsu Province (grant no. BE2020678).

Cite

APA

Huang, T., Zhang, B., Yang, Y., Lin, Q., & Shao, G. (2025). NSD3: A Promising Target for Cancer Therapy. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.70071

Vancouver

Huang T, Zhang B, Yang Y, Lin Q, Shao G. NSD3: A Promising Target for Cancer Therapy. Cell Biochemistry and Function. 2025. doi:10.1002/cbf.70071

BibTeX
@article{Huang2025,
  author = {Huang, Ting and Zhang, Bowen and Yang, Yifan and Lin, Qiong and Shao, Genbao},
  title = {NSD3: A Promising Target for Cancer Therapy},
  journal = {Cell Biochemistry and Function},
  year = {2025},
  doi = {10.1002/cbf.70071}
}
Start for free →